Instruction for use: Fenspiride

The Latin name of the substance Fenspiride

Fenspiridum (genus. Fenspiridi)

Chemical name

8- (2-Phenylethyl) -1-oxa-3,8-diazaspiro [4,5] decan-2-one (as hydrochloride)

Gross formula

C₁₅H₂₀N₂O₂

Pharmacological group:

H1-Antihistamines

The nosological classification (ICD-10)

J01 Acute sinusitis: Inflammation of the paranasal sinuses; Inflammatory diseases of the paranasal sinuses; Purulent-inflammatory processes of the paranasal sinuses; Infectious-inflammatory disease of ENT organs; Infection of the paranasal sinuses; Combined sinusitis; Exacerbation of sinusitis; Acute inflammation of the paranasal sinuses; Acute bacterial sinusitis; Acute sinusitis in adults; Subacute sinusitis; Sinusitis acute; Sinusitis

J02.9 Acute pharyngitis, unspecified: Purulent pharyngitis; Acute rhinopharyngitis; Lymphonodular pharyngitis

J04.0 Acute laryngitis: Lecter's laryngitis; Laryngitis acute catarrhal; Laryngitis acute phlegmonous

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J40 Bronchitis not specified as acute or chronic: Asthmatic bronchitis; Allergic bronchitis; Bronchitis allergic; Asthmatic bronchitis; Rhinotraheobronchitis; Asthmatic bronchitis; Bacterial bronchitis; Bronchitis; Bronchitis of the smoker; Bronchitis of smokers; Inflammation of the lower respiratory tract; Disease of the bronchi; Qatar smoker; Cough smokers; Cough with inflammatory diseases of the lungs and bronchi; Disturbance of bronchial secretion; Impaired bronchial function; Acute tracheobronchitis; Subacute bronchitis; Tracheobronchitis; Chronic lung diseases

J42 Chronic bronchitis, unspecified: Recurrent bronchitis; Asthmatic bronchitis; Asthmatic bronchitis; Bronchitis chronic; Inflammatory respiratory disease; Disease of the bronchi; Qatar smoker; Cough with inflammatory diseases of the lungs and bronchi; Exacerbation of chronic bronchitis; Chronic bronchitis; Chronic Obstructive Pulmonary Diseases; Chronical bronchitis; Chronic bronchitis of smokers; Chronic spasmodic bronchitis; Allergic bronchitis; Bronchitis allergic

J44 Other chronic obstructive pulmonary disease: Allergic bronchitis; Bronchitis allergic; Asthmatic bronchitis; Bronchitis obstructive; Disease of the bronchi; Difficult sputum separation in acute and chronic respiratory diseases; Cough with inflammatory diseases of the lungs and bronchi; Reversible bronchial obstruction; Reversible obstructive airway disease; Obstructive bronchial disease; Obstructive pulmonary disease; Obstructive bronchitis; Spastic bronchitis; Chronic lung diseases; Chronic nonspecific lung diseases; Chronic Obstructive Pulmonary Diseases; Chronic obstructive bronchitis; Chronic obstructive airways disease; Chronic obstructive pulmonary disease; Restrictive pathology of the lungs

J45 Asthma: Asthma of physical effort; Asthmatic conditions; Bronchial asthma; Bronchial asthma of light course; Bronchial asthma with difficulty in sputum discharge; Bronchial asthma of severe course; Bronchial asthma physical effort; Hypersecretory asthma; The hormone-dependent form of bronchial asthma; Curbing asthma attacks with bronchial asthma; Non-allergic bronchial asthma; Night Asthma; Exacerbation of bronchial asthma; Attack of bronchial asthma; Endogenous forms of asthma; Night attacks of asthma; Cough with bronchial asthma

R05 Cough: Severe cough; Cough; Cough in the preoperative period; Cough in allergic conditions; Cough with bronchitis; Cough with inflammatory diseases of the lungs and bronchi; Cough in diseases of the upper respiratory tract; Cough for colds; Cough with hard-to-remove viscous sputum; Cough with hard-to-recover sputum; Cough dry; Unproductive cough; Paroxysmal cough; Paroxysmal non-productive cough; Productive cough; Reflex cough; Coughing; Spasmodic cough; Dry cough; Dry, painful cough; Dry non-productive cough; Dry irritating cough; Cough with bronchial asthma; Cough with tuberculosis

CAS Code

5053-06-5

Pharmacology

Pharmacological action - Anti-inflammatory, bronchodilating, antihistamine, anti-asthmatic.

It blocks histamine H1 receptors, is an antagonist of inflammatory mediators (serotonin, histamine, bradykinin), has a papaverin-like spasmolytic effect. In high doses, it reduces the production of proinflammatory agents (cytokines, tumor necrosis factor alpha, arachidonic acid metabolites, free radicals), some of which have a bronchospastic effect. In experimental studies, the probability of a teratogenic effect (development of the "wolf mouth") was detected.

Well absorbed from the digestive tract, Cmax is achieved after 6 hours (tablets) or 2.3 hours (syrup); T1 / 2 - 12 hours. It is excreted mainly by the kidneys (90%) and the intestines (10%).

Application of substance Fenspiride

Rhinopharyngitis, laryngitis, rhinotraheobronchitis, otitis, sinusitis, chronic bronchitis with respiratory failure, bronchospastic syndrome, bronchial asthma (maintenance therapy), respiratory disorders in measles, pertussis, influenza.

Contraindications

Hypersensitivity, children under 14 years (for tablets).

Restrictions on the use

Pregnancy, breast-feeding.

Application in pregnancy and lactation

When pregnancy is possible, if the expected effect of therapy exceeds the potential risk to the fetus. Not recommended during lactation.

Side effects of the substance Fenspiride

On the part of the intestine: nausea, indigestion, pain in the stomach, vomiting.

From the side of the central nervous system: drowsiness, agitation.

From the cardiovascular system: rarely - tachycardia.

Allergic reactions: very rarely - erythema, Quincke's edema, fixed erythema pigment, rash, urticaria (due to the presence of parahydroxybenzoate in the syrup).

Overdose

Symptoms: drowsiness or agitation, nausea, vomiting, sinus tachycardia.

Treatment: gastric lavage, maintenance of vital functions; ECG monitoring is necessary.

Routes of administration

Inside.

Precautions for the substance Fenspiride

Sunset yellow S, which is part of the syrup as a dye, can provoke the development of allergic reactions, incl. Bronchospasm (especially in people with hypersensitivity to aspirin).